01 — At a Glance
The Boring Pharma Company That’s Anything But Boring
- Q3 FY26 Revenue₹210 Cr
- YoY Growth+21.4%
- Q3 PAT₹23.5 Cr
- PAT Growth YoY+29%
- Q3 EPS₹2.59
- EBITDA Margin20.8%
- 9M FY26 Revenue₹648.9 Cr
- 9M FY26 PAT₹69.3 Cr
- Book Value₹81.2
- Stock P/E39.3x
Ground Reality Check: SMS Pharmaceuticals just posted its strongest quarter in the fiscal year with ₹210 crore revenue (up 21% YoY), ₹44 crore EBITDA margin at 20.8% (31% YoY growth), and ₹23.5 crore PAT (29% up YoY). The stock is up 74% in one year. For context, this is an API manufacturer — a company that sells fancy salt molecules to other pharma companies. Not VR. Not Crypto. Not even a “platform play.” Just molecules and math.
02 — Introduction
Why Should You Care About A Company That Makes Aspirin Building Blocks?
SMS Pharmaceuticals is not a household name. Your neighbour has never asked, “Arre, have you invested in SMS?” Your barber doesn’t mention it. Your WhatsApp group doesn’t flood with SMS “tips” at 2 AM. It’s an API (Active Pharmaceutical Ingredient) manufacturer. That means they make the raw materials that Cipla, Aurobindo, Lupin, and every other pharma company use to make the medicines that actually cure your headache.
Here’s the thing: nobody watches API makers because APIs are boring, commoditized, and low-margin. Or they were boring. SMS Pharma has spent the last 3-4 years building backward integration capabilities, launching the world’s largest automated ibuprofen plant in Asia, and shipping 1,100 MT of anti-diabetic APIs annually. That’s not boring. That’s a company printing cash and reinvesting it like a person with a actual long-term plan.
By Q3 FY26, the backward integration thesis is coming home to roost. EBITDA margins just crossed 20% — something most of their peers cannot dream of. The stock is trading at 39.3x P/E. Market is saying: “Yes, we know it’s an API company. But it’s a GOOD API company.” And the market’s not entirely wrong.
Let’s dig into what just happened in the quarter, because Q3 FY26 is the proof point that all those capex investments from the last cycle are now moving the needle.
Management Says: “Revenue grew 21% YoY, on the back of strong volume growth in key APIs. EBITDA margin above 20%; up by 31% YoY aided by operating leverage.” Translation: We spent ₹280 crore on building factories. Now those factories are full. Party time.
03 — Business Model: What Does SMS Actually Do?
They Make The Stuff That Makes The Stuff That Cures Stuff
SMS Pharma manufactures Active Pharmaceutical Ingredients (APIs) and intermediates. In plain English: they take raw chemicals (many imported from China), blend them using proprietary processes, and sell them to other pharma companies. These pharma companies then blend those APIs with fillers, wrap them in a pill or tablet, slap a brand name on it, and sell it to your neighbourhood chemist. It’s a three-tier value chain: SMS → Cipla/Lupin/etc → Your chemist → You.
The company operates two facilities: one in Hyderabad (120 KL reactor capacity, niche small-volume molecules) and one in Vizag (3,000 KL reactor capacity, large-volume APIs). They sell 55+ APIs to 800+ customers across 75+ countries. Top 5 customers account for ~55% of revenue. That’s customer concentration that would make most CEOs nervous, but SMS management sleeps fine because these are marquee pharma companies with long-standing relationships.
The revenue mix is diversified across 14 therapeutic areas: Anti-diabetic (19%), Anti-Retroviral/ARV (28%), Anti-inflammatory (20%), Anti-migraine (11%), Anti-ulcer (4%), and others. The real magic is that they’re not just manufacturing – they’re now backward integrating. They’re building capacity to make starting materials (KSMs) that they used to import. That cuts costs and improves margins. Simple, but powerful.
Revenue from Regulated Markets88%FDA/EMA approved
DMF Filings120+Regulatory track record
Global Presence75+Countries served
The Ibuprofen Story: SMS built Asia’s largest dedicated automated ibuprofen production block a few years back. They started selling it at negative margins to grab market share. By FY25-26, they’ve scaled it to 3,000 MT annually and the margins are healthy. This is textbook pharma execution: lose money on scale-up, then print money on volume. They’re now the world’s largest ibuprofen producer. Not bad for a company founded in 1989 in Hyderabad.
💬 Tell us: How many of you have taken an SMS Pharma API without knowing it? (Spoiler: Probably most of you who’ve taken an Aurobindo or Cipla medicine.)
04 — Financials: The Numbers That Matter
Q3 FY26: Where The Backward Integration Bet Is Actually Paying Off
Result Type: Quarterly Results | Q3 FY26 EPS: ₹2.59 | Annualised EPS (Q3×4): ₹10.36 | FY25 Full-Year EPS: ₹7.71
| Metric (₹ Cr) |
Q3 FY26
Dec 2025 |
Q3 FY25
Dec 2024 |
Q2 FY26
Sep 2025 |
YoY % |
QoQ % |
| Revenue | 210.45 | 173.35 | 242.43 | +21.4% | -13.2% |
| EBITDA | 43.65 | 33.21 | 48.38 | +31.3% | -9.8% |
| EBITDA Margin % | 20.8% | 19.2% | 20.0% | +160 bps | +80 bps |
| PAT | 23.47 | 18.24 | 25.32 | +28.6% | -7.3% |
| EPS (₹) | 2.59 | 2.15 | 2.84 | +20.5% | -8.8% |
The Seasonality Dance: Q3 usually softer than Q2 in this space due to generics market dynamics and customer inventory adjustments. But even at ₹210 Cr revenue, growth is 21% YoY. The real win: EBITDA margin at 20.8% — this is where backward integration is showing teeth. Cost of goods sold is down, operating leverage is up, and the company is finally executing at scale. At an annualized EPS of ₹10.36 (Q3×4), the stock’s 39.3x P/E is starting to look less insane.
05 — Valuation: Fair Value Range
Is ₹366 Per Share Reasonable? Or Are We In Bubble-Land?
Method 1: P/E Based
FY25 full-year EPS = ₹7.71. Annualised Q3 FY26 EPS (Q3×4) = ₹10.36. Midpoint: ₹9.00. Pharma industry median P/E = 27.2x. SMS trades at 39.3x. Justified premium for backward integration and margin expansion: 1.2x–1.5x median. Fair P/E band: 32x–41x.
Range: ₹288 – ₹369
Method 2: EV/EBITDA Based
TTM EBITDA (FY25 annual + 9M FY26) ≈ ₹180 Cr. Current EV = ₹3,658 Cr. EV/EBITDA = 20.3x. Quality API makers trade at 12x–18x. SMS premium justified by superior margins.
EV range (14x–20x EBITDA): ₹2,520 Cr – ₹3,600 Cr → Per share:
Range: ₹270 – ₹385
Method 3: DCF Based
Base FCF: ₹82 Cr (FY25 operating CF). Growth: 18–22% for next 5 years (supported by capex, backward integration). Terminal growth: 4%. WACC: 10%.
→ PV of 5-year FCFs at 10%: ~₹600 Cr
→ Terminal Value (4% growth / 6% cap rate): ~₹3,200 Cr
→ Total EV: ~₹3,800 Cr (accounting for capex completion)
Range: ₹305 – ₹410
⚠️ EduInvesting Fair Value Range: ₹270 – ₹410. Current price ₹366 sits squarely in the middle-to-upper part of the range. This fair value range is for educational purposes only and is not investment advice. Please consult a SEBI-registered investment advisor before making any financial decision.
06 — What’s Cooking: News, Triggers & Drama
Capital Gains Theatre: Warrants, Capex, And USFDA High-Fives
